Neal Bibeau is a healthcare/pharma IT solutions executive with a unique track record building organizations recognized for innovation, agility and responsiveness in the healthcare analytics and data sector.
Mr. Bibeau recently served as the President and CEO of Symphony Health Solutions, a top real-world health data, analytics and software business with over $200 million in revenue, which was acquired by PRA Health Sciences. There, he successfully transformed the business from health data publishing and consulting into a technology and data analytics platform, achieving substantial growth in the business. Mr. Bibeau received a B.A. in Economics and Government from Dartmouth College, as well as a M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.
Michael W. Fried, MD, FAASLD
Co-Founder & Chief Medical Officer
Michael W. Fried, MD, FAASLD, co-founder and Chief Medical Officer for Target RWE, is Professor of Medicine in the Division of GI and Hepatology at the University of North Carolina at Chapel Hill. Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for more than 20 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the NIH Hepatitis B Research Network.
Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C. Dr. Fried and HCV-TARGET colleagues were awarded the Regulatory Science Excellence Award by the FDA in 2018 for their contributions of real-world evidence regarding the safety and effectiveness of hepatitis C therapeutics.
Dr. Fried is the primary author or co-author on over 200 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. His manuscript on therapy of hepatitis C, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.
Dr. Fried served on the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and was the president of AASLD in 2019.
Chief Business Officer
Matt Casbon is currently serving as Chief Business Officer for Target RWE Health Evidence Solutions.
Prior to joining Target RWE, Matt was Senior Vice President of Global Strategic Marketing at Circassia where he was responsible for global marketing, research sales and training.
Prior to Circassia, Matt worked as the Vice President of Marketing at KemPharm. Matt also previously worked at Chimerix, Salix Pharmaceuticals, Abbott Laboratories, and Solvay Pharmaceuticals in various roles of increasing responsibility.
He brings over 25 years of sales and marketing experience, including business development evaluations, product launches, pre-commercial strategy planning and sales force operations.
Matt received his BA from the West Chester University.
Senior Vice President, Clinical Operations
Laura Malahias has over 13 years of experience working in clinical research including assignments on all sides of the industry from study site, small and large CROs, to pharma. She is currently serving as Senior Vice President of Clinical Operations at Target RWE Health Evidence Solutions. Prior to her work at Target RWE, Laura worked at Aerial BioPharma where she played an integral role in the development of ADX-N05 (Solriamfetol) which was sold to Jazz Pharmaceuticals.
Vice President, Enterprise Architecture
Viswa has more than 19 years of proven experience spanning analytics, machine learning, application development, and software engineering. Most recently, he served as VP of Architecture and R&D at Symphony Health Solutions where he architected and built various machine learning and analytics toolsets.
In his past experience, Viswa has designed and developed several complex systems including “The (Microbiology) Surveillance Network”, Electronic Lab, and Clinical Analytics Architecture framework.
Viswa earned his degree in electrical engineering; however, his professional experience has focused on healthcare and life sciences.
Vice President, Technology
Jason Fox is currently serving as Vice President of Technology at Target RWE.
Jason has over 15 years’ experience in software engineering and architecture, including stints at NASA’s Jet Propulsion Laboratory and SAS. Jason is an expert in building high performing, highly available software systems for a wide array of industries. Whether it is mission support software for robotic exploration of Mars, or scalable frameworks for high-end analytics, Jason brings his methodical approach and deep understanding of computer systems to solving difficult problems.
Jason received his Master’s degree in Computer Science from Purdue University and his Bachelors in Computer Science Engineering from The Ohio State University.
Vice President, Finance
Jennifer (Jen) Woods is currently serving as Vice President of Finance for Target RWE.
Jen Woods has over 15 years of experience in the accounting and finance industry serving a variety of sectors, including life sciences, telecommunications, and banking. Before joining TARGET, Jen held various positions at Ernst & Young, LLP, the American Institute of CPAs, and Wachovia Bank. Most recently, she served in accounting and finance roles for private companies and non-profits. Jen is a client-focused, team player with strong communication skills and a proven track record of managing assignments and directing teams of professionals to produce results.
Senior Director, Legal Affairs
Allison joined Target RWE in January 2018 and is currently serving as Senior Director of Legal Affairs.
Allison’s experience includes several years serving as Assistant General Counsel of the Oklahoma Corporation Commission, specializing in public utilities regulation, before moving to North Carolina for her husband’s medical residency.
After moving to Chapel Hill, Allison consulted for Core Grammar for Lawyers, an online learning tool for law students and practicing attorneys, to edit and test the program before its release. Allison then went on to succeed in accomplishing both a career change and re-entry into the workforce, after spending time at home with her young children, when she accepted a position managing contracts in Site Start Up with Syneos Health before joining Target RWE. As a member of the Target RWE team, Allison enjoys navigating the complexities of the developing field of Real-Word Evidence with her remarkable colleagues each day.
Senior Director, Human Resources
Melissa is currently serving as Senior Director of Human Resources at Target RWE. Melissa Mulauski has over 18 years of human resources experience in employee relations, training, policy development, compensation, and recruiting.
Melissa spent 6 years working at Quintiles in their Human Resources department and another 3 years heading the Human Resources department at Peopleclick before joining Strategic HR Solutions as a Consultant.
Melissa is professionally certified as a Senior Professional in Human Resources (SPHR) and also as a SHRM Senior Certified Professional (SCP). She holds a Bachelor of Science degree in Labor and Industrial Relations with a Business minor from The Pennsylvania State University.
Richard C. Zink, PhD
Senior Director, Data Management & Statistics
Richard joined Target RWE in 2018 after seven years in the JMP Life Sciences division at SAS Institute, where he developed software to assess safety and data integrity in clinical trials utilizing CDISC standards.
Prior to SAS, he spent eight years in the pharmaceutical industry, where he designed and analyzed clinical trials in diverse therapeutic areas including infectious disease, oncology, and ophthalmology, and participated in US and European drug submissions and FDA advisory committee hearings. Richard is the 2019 Chair of the Biopharmaceutical Section of the American Statistical Association, host of the Biopharmaceutical Section Statistics Podcast, and Associate Editor for the DIA journal Therapeutic Innovation & Regulatory Science.
His research interests include data visualization, the analysis of pre- and post-market adverse events, subgroup identification for patients with enhanced treatment response, and the assessment of data integrity in clinical trials, and he participates in scientific working groups for safety and real-world evidence. Richard is the author of Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS, the co-editor of Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods, and a contributor to six other books on statistical topics in clinical trials and clinical research. He holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, where he serves as Adjunct Assistant Professor of Biostatistics. Richard was awarded the distinction of Fellow of the American Statistical Association in 2020.
Meg Powell, PharmD
Co-Founder and Board Chair
Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as Board Chair and is the Co-Founder of Target RWE.
She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.
Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
Eric Edell is Co-Founder and Co-Managing Partner of 22C Capital, a private equity firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption. The Firm has a dedicated focus on the healthcare services, business services, and financial services sectors. 22C's operational and technology resources, including its affiliated data science organization strive to deliver practical, real-world support to help convert these businesses' challenges into opportunities and unlock their full potential.
Mr. Edell received his B.A. in Neuroscience, summa cum laude, from the University of Pennsylvania, where he was a member of Phi Beta Kappa. He lives in New York City with his wife, Deborah, and their three children.
Ryan A. Harris, MD
Ryan Harris, MD brings more than twenty-five years of healthcare experience and fifteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include Blue Cloud, Onsite Dental, and Rivermend Health. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps.
At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.
Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.
Dr. Harris holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
Mike McKelvey, PhD
Mike McKelvey, PhD, brings nearly three decades of experience building successful global organizations in the pharmaceutical services, healthcare IT, life sciences, technology and global core laboratory industries. A results-oriented, hands-on leader, he oversees an organization of 14,000 professionals with deep therapeutic capabilities in Phase I-III services, FSP services, Real World and Late Stage services, and Early Stage clinics and laboratories.
Before joining Syneos Health, he served as Executive Vice President and Chief Operating Officer at Aptiv Solutions, a global clinical development services company focused on adaptive clinical trial design. Aptiv Solutions was acquired by ICON in 2014. Prior to Aptiv Solutions, he was President and CEO and a board member of eResearch Technology, Inc. (ERT), a multiproduct provider of clinical research services. Prior to ERT, Dr. McKelvey led PAREXEL's Phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.
Throughout his career, Mike has developed a reputation for combining high-level strategic expertise with flawless execution.
Mr. McKelvey holds a Ph.D. and M.A. in Business Economics from the Wharton School at the University of Pennsylvania and an A.B. degree in Economics from Williams College.
Franz Humer, PhD
Dr. Humer is Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is also a Non-Executive Director of the Board at Allogene Therapeutics, the Chairman of PCI Services and an Advisor to Temasek Holdings and Letterone Healthcare.
Before joining Roche Group, he was the managing director of Glaxo Pharmaceuticals UK Ltd. was elected to the Board of Glaxo Holdings plc and progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Franz joined Schering-Plough Corporation, where he held various general management positions in Latin America and Europe. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its pharmaceuticals division, progressing to become Chairman and CEO in 2001, and between 2008 and 2014 the Chairman of Roche Holding Limited. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Franz earned a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France.